Good afternoon. I'm Joel Ackerman, the CEO of Champions Oncology. Thank you for joining us for our quarterly earnings call. I'll start the call today with highlights and updates since our last call on issues of strategic importance for the company, then discuss the financial results, and finally open the call up for questions. Before I start, I will remind you that I will make forward-looking statements during the call and actual results could differ materially from what is described in those statements. Additional information on factors that could cause results to differ is available in our Forms 10-Q and Form 10-K. Reconciliation of the non-GAAP financial measures that may be discussed on the call to GAAP financial measures is available in the earnings release. Before I get into the specifics, I believe that this quarter was a real turning point for Champions. We’ve been building this company for five years now with a goal of demonstrating the power and potential of patient derived xenografts and the unique approach Champions has pursued in building our platform. The path we took was both risky and expensive. It resulted in significantly higher R&D expenses and cash burn than we would have incurred had we decided to just build a preclinical CRO business. We pursue this path because we know the difference and value that can be achieved by building and growing scientifically-driven platforms with sustainable competitive advantages as compared to even the best service businesses. Over time, companies with unique technology platforms generate higher revenue growth, better profit margins and larger multiples and this is what we said have to achieve. We believe the accomplishments of this quarter represent a series of significant milestones in demonstrating our progress and differentiation as a truly unique company serving a huge unmet need and a…

[Operator Instructions] And your first question comes from the line of Tom Shelton. Mr. Shelton, your line is live.

Great. Congratulations. It sounds like you are making really good progress.

Thank you.

I just got one question. A little curious that one is, our potential programs going forward is studying AML? I have seen some recent – really good results at ASH on some compounds on AML, but I am curious as to your appeal is to lives of interest in that AML is a fairly slow market. Is it because of some blood cancer and you can see results quickly or what are the distinguishing are that make that so much interest?

I think it’s a good question and I don’t know to try about – a tremendous amount of insight on the issue. I think the reason of primary interest for our customers right now is that it is a disease, it is a subset of cancer where there is very little that can be done in terms of animal modeling today. And adding to their capabilities to model the disease I think will be a huge step forward relative to the current availability of models and I think that has been the primary driver of the interest from our customers. It is still at the level of unmet need from other in-vivo modeling capabilities.

Okay, great. Thank you.

You are welcome.

[Operator Instructions] And at this time, there are no questions. Thank you.

Great. Well, thank you everyone. I appreciate your calling in. We look forward to updating you next quarter. Thanks.

This concludes this afternoon’s teleconference. You may now disconnect your lines.